LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor (antagonist) with IC50 of 14.93 μM. LCH-7749944 effectively suppresses the proliferation/growth of human gastric cancer/tumor cells and causes apoptosis by down-regulating the PAK4/c-Src/EGFR/cyclin D1 pathway.

Physicochemical Properties

Molecular Formula	C20H22N4O2
Molecular Weight	350.41
Exact Mass	350.174
Elemental Analysis	C, 68.55; H, 6.33; N, 15.99; O, 9.13
CAS #	796888-12-5
Related CAS #	796888-12-5;1049788-58-0 (HCl);
PubChem CID	2951910
Appearance	white solid powder
Density	1.3±0.1 g/cm3
Boiling Point	580.0±58.0 °C at 760 mmHg
Flash Point	304.6±32.3 °C
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.680
LogP	2.18
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Heavy Atom Count	26
Complexity	438
Defined Atom Stereocenter Count	0
SMILES	N1C2C(=CC=CC=2)C(NCC2CCCO2)=NC=1NC1C=C(OC)C=CC=1
InChi Key	FBWZAFQEOKNGQL-UHFFFAOYSA-N
InChi Code	InChI=1S/C20H22N4O2/c1-25-15-7-4-6-14(12-15)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-26-16/h2-4,6-7,9-10,12,16H,5,8,11,13H2,1H3,(H2,21,22,23,24)
Chemical Name	2-N-(3-methoxyphenyl)-4-N-(oxolan-2-ylmethyl)quinazoline-2,4-diamine
Synonyms	GNF-PF-2356; LCH 7749944; LCH-7749944; LCH7749944
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	PAK4 (IC50 = 14.93 μM)
ln Vitro	In a concentration-inhibitory manner, LCH-7749944 (GNF-PF-2356; 5-50 μM; 24 hours) reduces the proliferation of MKN-1, BGC823, SGC7901, and MGC803 cells [1]. 12 LCH-7749944 (5 -20 μM) The application of LCH-7749944 (5 – 20 μM; 12-48 hours) to promote SGC7901 cell counts[1] results in a dose-monitored rise in the total number of cells in the G1 phase and a decrease in the total number of cells in the S phase.
Cell Assay	Cell Proliferation Assay[1] Cell Types: -7749944 (5-30 μM; 24 hrs (hours)) Dramatically reduces phosphPAK4, phospho-c-Src, phospho-EGFR and cyclin D1 protein expression levels in a dose-dependent manner[1]. MKN-1, BGC823, SGC7901 and MGC803 human gastric cancer cells Tested Concentrations: 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of MKN-1, BGC823, SGC7901 and MGC803 cells in a concentration-dependent manner. Apoptosis analysis [1] Cell Types: SGC7901 Cell Tested Concentrations: 5, 10, 20 μM Incubation Duration: 12, 24, 48 hrs (hours) Experimental Results: Induced apoptosis of SGC7901 cells. Cell cycle analysis [1] Cell Types: SGC7901 Cell Tested Concentrations: 5, 10, 20 μM Incubation Duration: 12, 24, 48 hrs (hours) Experimental Results: Dramatically induced a dose-dependent increase in the percentage of cells in G1 phase and a decrease in the percentage of cells in S phase. Western Blot Analysis [1] Cell Types: SGC7901 Cell Tested Concentrations: 5, 10, 20, 30 μM Incubation Duration: 24 hrs (hours) Experimental Results: Phosphorylated PAK4, phos
References	[1]. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett. 2012 Apr 1;317(1):24-32.

Solubility Data

Solubility (In Vitro)

DMSO: 70~250 mg/mL (199.8~713.5 mM) Ethanol: ~70 mg/mL (~199.78 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.17 mg/mL (6.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (6.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.8538 mL	14.2690 mL	28.5380 mL
	5 mM	0.5708 mL	2.8538 mL	5.7076 mL
	10 mM	0.2854 mL	1.4269 mL	2.8538 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.